We're here to help during Covid-19. Find out more here.
This study will determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer.
Who is it for?
You may be eligible for this study if you meet the below criteria:
Participants will receive either endocrine monotherapy as per physician choice or daily SAR439859 dose administered orally. The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to four weeks (28 days), a treatment period of at least one cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant's request.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com
Subscribe for updates & stay in the loop with new studies.